Mr. Miguel Martin of Aurora reports

AURORA CANNABIS REFUTES CURALEAF'S LATEST ATTEMPT TO DISTRACT SHAREHOLDERS FROM THE FACTS

Aurora Cannabis Inc. has responded to the application by Curaleaf Holdings Inc. to halt Aurora's at-the-market program.

Aurora believes Curaleaf's filing is simply the latest attempt to distract shareholders from the fundamental issue before them: Curaleaf's hostile bid significantly undervalues Aurora and seeks to acquire Aurora's cash, unique European Union good manufacturing practice assets, global growth platform and future upside at a discount.

Aurora's ATM program was publicly announced in February, 2026, over six months before Curaleaf launched its hostile bid, as part of the company's long-term international growth strategy. The program was established to provide Aurora with flexibility to pursue strategic and accretive opportunities that support long-term shareholder value, including increased cultivation capacity and mergers and acquisitions.

"Curaleaf is attempting to spin a story that simply does not align with the facts," said Miguel Martin, executive chairman and chief executive officer of Aurora. "Our ATM program was established long before Curaleaf launched its inadequate hostile bid and was never designed as a response to it. It is a long-standing capital allocation tool that supports Aurora's growth strategy. Our most recent acquisitions in the U.K. that unlock our access to this critical market is a direct example of responsible use of funds generated from the ATM," Mr. Martin added.

"Curaleaf is trying to suggest that the existence of the ATM program somehow says something about the value of Aurora's business. It does not. The question for shareholders is whether Curaleaf's hostile offer fairly compensates them for the company they own today and the future value they are being asked to give up. We do not believe it does.

"The board's responsibility is to maximize value for Aurora shareholders, not to make Aurora easier or cheaper for Curaleaf to acquire," concluded Mr. Martin. "The ATM program will continue to be used only when the board determines it is in the best interests of the company to do so, having regard to all relevant factors."

Aurora shareholders are reminded that the company is debt-free and maintains a strong cash position, providing the flexibility to continue investing in growth, innovation and strategic opportunities. Aurora believes shareholders should carefully consider whether exchanging ownership in a debt-free company with a proven international growth strategy for shares in a company carrying more than $1-billion of debt, concentrated voting control, and additional governance and regulatory risks is in their best interests.

On Sept. 2, Aurora's board of directors filed a director circular, which unanimously recommended that shareholders reject Curaleaf's hostile bid by taking no action and not tendering their shares. The board unanimously recommends that any Aurora shareholders who have tendered their shares to the hostile bid withdraw those shares.

Curaleaf's latest application does not change the board's view that its hostile bid is inadequate and fails to reflect the value of Aurora's business or the opportunities ahead.

Shareholder assistance

Shareholders with questions about the hostile bid or who would like to receive continuing updates may contact Kingsdale Advisors, Aurora's strategic adviser and information agent:

• Toll-free (within North America): 1-800-749-9052;
• Call or text: 416-623-4172;
• E-mail: contactus@kingsdaleadvisors.com.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands, including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corp. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

Aurora's common shares trade on Nasdaq and the Toronto Stock Exchange under the symbol ACB.

We seek Safe Harbor.